Therapeutics News

NASHVILLE, Tenn. — Short-term noninvasive tear breakup time increased with use of Lumify eye drops in cohort of patients with and without dry eye disease, according to a poster presented at Optometry’s Meeting.

NASHVILLE, Tenn. — A preservative-free brimonidine tartrate ophthalmic solution was statistically noninferior to Bausch + Lomb’s Lumify, offering an alternative option for ocular redness relief, according to a poster at Optometry’s Meeting.

Vevye, a nonpreserved cyclosporine 0.1% ophthalmic solution, demonstrated sustained safety and efficacy among patients with dry eye disease, according to 52-week ESSENCE-2 open-label extension study results published in Cornea.

Opthea has completed enrollment of its phase 3 COAST and ShORe trials, which will investigate the safety and efficacy of sozinibercept in combination with anti-VEGF-A therapy for wet age-related macular degeneration.

Lubricating eye drops with a single-polymer or dual-polymer formulation and saline were all effective in reducing epithelial surface irregularity along the horizontal meridian in a study published in Optometry and Vision Science.

EyeCRO announced that its Microemulsion Drug Ocular Penetration System, or MiDROPS, demonstrated safety and efficacy in its first clinical application as a topical eye drop vehicle for dry eye disease.

Aldeyra Therapeutics has enrolled the first patient in a phase 3 clinical trial designed to allow possible resubmission of the new drug application of topical 0.25% reproxalap for dry eye disease, according to a company press release.

Qlaris Bio raised $24 million during series B financing for the clinical development of QLS-111, a new IOP-lowering drug candidate for patients with glaucoma, the company announced in a press release.

Ocugen has announced that dosing is complete in the second cohort of its phase 1/2 ArMaDa clinical trial to assess the safety of OCU410, a modifier gene therapy candidate for geographic atrophy.

Oral minocycline was not associated with a reduction in geographic atrophy enlargement over 24 months vs. a 9-month run-in period among patients with age-related macular degeneration, according to a study in JAMA Ophthalmology.